1. Home
  2. M vs RYTM Comparison

M vs RYTM Comparison

Compare M & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Macy's Inc

M

Macy's Inc

HOLD

Current Price

$25.28

Market Cap

6.7B

ML Signal

HOLD

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

HOLD

Current Price

$89.99

Market Cap

5.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
M
RYTM
Founded
1830
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Department/Specialty Retail Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.7B
5.8B
IPO Year
2002
2017

Fundamental Metrics

Financial Performance
Metric
M
RYTM
Price
$25.28
$89.99
Analyst Decision
Hold
Strong Buy
Analyst Count
13
14
Target Price
$20.09
$131.14
AVG Volume (30 Days)
7.2M
555.5K
Earning Date
05-27-2026
05-05-2026
Dividend Yield
3.97%
N/A
EPS Growth
12.08
28.34
EPS
0.23
N/A
Revenue
$22,621,000,000.00
N/A
Revenue This Year
N/A
$55.34
Revenue Next Year
N/A
$86.06
P/E Ratio
$108.63
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.99
$60.99
52 Week High
$25.65
$122.20

Technical Indicators

Market Signals
Indicator
M
RYTM
Relative Strength Index (RSI) 71.92 54.54
Support Level $16.74 $82.43
Resistance Level N/A $92.51
Average True Range (ATR) 1.09 4.22
MACD 0.32 0.24
Stochastic Oscillator 93.12 48.58

Price Performance

Historical Comparison
M
RYTM

About M Macy's Inc

Founded in 1858 and based in New York City, Macy's operates about 430 eponymous stores, 60 stores under the Bloomingdale's (full-price and outlet) and Bloomie's names, and more than 170 freestanding Bluemercury specialty beauty stores. Macy's also operates e-commerce sites and licenses Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances constituted 64% of 2025 net retail sales.

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Share on Social Networks: